STAT News

STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more

Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths

By STAT News

1 min read
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights